Bayer's Xarelto® (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism (PE) and the Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE in the EU Blood clots obstructing blood flow in ...

CHICAGO, IL—A fixed dose of the oral factor X inhibitor rivaroxaban is noninferior to standard therapy with enoxaparin and a vitamin K antagonist in patients with acute symptomatic pulmonary embolism ...

Rivaroxaban demonstrated favorable outcomes and cost savings in patients with deep vein thrombosis and pulmonary embolism when used for at-home treatment after discharge from the emergency room, ...

The “triple aim” promised by healthcare reform—better-quality care, greater patient satisfaction, at a lower cost—will play out procedure by procedure as physicians find ways to deliver better ...

Please provide your email address to receive an email when new articles are posted on . The prospective, multinational, investigator-initiated, single-arm, phase 4 HoT-PE trial included adults with ...

NEW YORK (AP) — Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence ...

Pulmonary embolism (acute treatment, VTE prevention - rivaroxaban: appendix A draft scope for consultation (post referral) October 2012 Pulmonary embolism (acute treatment, VTE prevention - ...

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...

Janssen and Bayer announced new data from two real-world studies that confirmed the positive benefit-risk profile of Xarelto (rivaroxaban) for the treatment of venous thromboembolism (VTE) and ...

The FDA has approved Xarelto (rivaroxaban; Janssen) for the prophylaxis of venous thromboembolism (VTE) and VTE-related death during hospitalization and post hospital discharge in adult patients ...

DUBLIN--(BUSINESS WIRE)--The "Drug analysis: Xarelto" drug pipelines has been added to ResearchAndMarkets.com's offering. Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant ...

The triple aim promised by healthcare reform-better quality care, greater patient satisfaction, at a lower cost-will play out procedure by procedure, as physicians find ways to deliver better care and ...